Jaguar Health, Inc.
For the period ended Dec 31, 2024. Filed Mar 31, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 31, 2025
JAGX$0.44+0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets as of December 31, 2024 and
| December 31, · December 31, | ||||
|---|---|---|---|---|
| (In thousands, except share and per share data) · 2024 · 2023 | ||||
| Assets | ||||
| Current assets: | ||||
| Cash | $ | 8,002 | $ | 6,469 |
| Accounts receivable, net | 1,527 | 1,967 | ||
| Other receivable | 120 | 217 | ||
| Inventory | 10,345 | 9,189 | ||
| Prepaid expenses and other current assets | 12,204 | 10,121 | ||
| Total current assets | 32,198 | 27,963 | ||
| Property and equipment, net | 464 | 496 | ||
| Operating lease - right-of-use asset | 936 | 1,176 | ||
| Intangible assets, net | 18,479 | 20,116 | ||
| Other assets | 1,348 | 1,012 | ||
| Total assets | $ | 53,425 | $ | 50,763 |
| Liabilities, Redeemable preferred stock, and Stockholders' equity | ||||
| Current liabilities: | ||||
| Accounts payable | $ | 5,286 | $ | 4,974 |
| Accrued liabilities | 1,911 | 3,798 | ||
| Deferred revenue | 170 | — | ||
| Operating lease liability, current | 299 | 348 | ||
| Notes payable, net of discount (includes note designated at Fair Value Option amounting to $11.9 million as of December 31, 2024, and $0 December 31, 2023, respectively) | 12,038 | 4,867 | ||
| Total current liabilities | 19,704 | 13,987 | ||
| Operating lease liability, net of current portion | 686 | 886 | ||
| Deferred revenue - long term | 553 | — | ||
| Notes payable, net of discount, net of current portion (includes notes designated at Fair Value Option amounting to $21.7 million as of December 31, 2024, and $31.0 million December 31, 2023, respectively) | 23,503 | 30,993 | ||
| Total liabilities | 44,446 | 45,866 | ||
| Commitments and contingencies (See Note 6) | ||||
| Redeemable preferred stock: $0.0001 par value; 178 and 0 shares designated from 10,000,000 preferred stock authorized at December 31, 2024, and December 31, 2023; 99 and 0 shares issued and outstanding at December 31, 2024 and December 31, 2023 | 2,485 | — | ||
| Stockholders' equity | ||||
| Series G convertible preferred stock: $0.0001 par value; 137 and 137 shares designated from 10,000,000 preferred stock authorized at December 31, 2024, and December 31, 2023; 0 and 122 shares issued and outstanding at December 31, 2024 and December 31, 2023 | — | — | ||
| Series H convertible preferred stock: $0.0001 par value; 105 and 105 shares designated from 10,000,000 preferred stock authorized at December 31, 2024, and December 31, 2023; 0 shares issued and outstanding at December 31, 2024 and December 31, 2023 | — | — | ||
| Series I convertible preferred stock: $0.0001 par value; 118 and 118 shares designated from 10,000,000 preferred stock authorized at December 31, 2024, and December 31, 2023; 0 and 56 shares issued and outstanding at December 31, 2024 and December 31, 2023 | — | — | ||
| Common stock - voting: $0.0001 par value, 298,000,000 shares authorized at December 31, 2024, and December 31, 2023; 528,440 and 48,942 issued and outstanding at December 31, 2024, and December 31, 2023 | — | — | ||
| Common stock - non-voting: $0.0001 par value, 50,000,000 shares authorized at December 31, 2024, and December 31, 2023; 9 shares issued and outstanding at December 31, 2024, and December 31, 2023 | — | — | ||
| Additional paid-in capital | 354,234 | 313,862 | ||
| Noncontrolling interest | (791) | (64) | ||
| Accumulated deficit | (346,482) | (308,249) | ||
| Accumulated other comprehensive loss | (467) | (652) | ||
| Total stockholders' equity | 6,494 | 4,897 | ||
| Total liabilities, redeemable preferred stock and stockholders' equity | $ | 53,425 | $ | 50,763 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.